Compare VIOT & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIOT | FLNA |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | China | United States |
| Employees | N/A | 20 |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.9M | 61.8M |
| IPO Year | 2018 | N/A |
| Metric | VIOT | FLNA |
|---|---|---|
| Price | $0.80 | $1.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 206.1K | ★ 320.5K |
| Earning Date | 03-25-2026 | 05-13-2026 |
| Dividend Yield | ★ 13.49% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.04 | N/A |
| P/E Ratio | $3.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.74 | $1.15 |
| 52 Week High | $4.33 | $2.03 |
| Indicator | VIOT | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 38.28 | 44.72 |
| Support Level | N/A | $1.16 |
| Resistance Level | $1.05 | $1.80 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 32.46 | 44.44 |
Viomi Technology Co Ltd, along with its subsidiaries, specializes in the development and sale of Internet-of-Things-enabled smart home products, particularly focusing on home water solutions. The company markets its products in China and generates the majority of its revenue through the sale of smart water purification systems and other connected home devices designed to improve convenience and automation in residential settings. Its product offerings include water purification products, water heaters, smart water kettles, electric kettles, water filters, range hoods, gas stoves, and other small appliances.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.